pembrolizumab + chemotherapy for high-risk, early-stage TNBC showed manageable toxicity and promising antitumor activity, and the pCR rate showed a positive correlation with tumor PD-L1 expression and sTIL levels. This evidence concerns the gene CD274 and neoplasm.